Sun, Apr 20, 2014, 6:23 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

checksurshorts 140 posts  |  Last Activity: Apr 16, 2014 2:35 PM Member since: Dec 1, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Update from NTM Patient

    by checksurshorts Apr 16, 2014 2:33 PM
    checksurshorts checksurshorts Apr 16, 2014 2:35 PM Flag

    More:

    "I posted an answer to this earlier, but I was involved in the trial and it was great. The drug can cause hoarseness or even loss of voice temporarily, but, for me, it was totally worth it -- 4+ years of the Big 3 with no change in MAC status, and now, thanks to Arikayce, I've been MAC-free for a year. I was in the placebo group to begin with, so my results were not included in the research report, but got the actual drug for the second 12 weeks."

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Apr 16, 2014 2:33 PM Flag

    "I was in the trial. It was great. After more than 4 years of constant MAC-positive results on the Big 3, I have now been MAC-negative since concluding the trial last February (latest check-up was February of this year). In the published results, I would have been included in the placebo group, but all of the participants were able to take the actual drug for the second 12 weeks if they chose to. Am I glad I did. I don't know if the drug will work for everyone, but it has been a dream for me. Really hope they speed up the approval process (maybe skip Phase III tests due to "compassionate use")."

    Sentiment: Strong Buy

  • Reply to

    The market does really tidy work :-)

    by fudfighter4 Apr 15, 2014 9:13 AM
    checksurshorts checksurshorts Apr 15, 2014 9:40 AM Flag

    I noticed the tidy one-dollar increments as well but didn't bring up for fear of being accused of wearing a tin-foil hat.

    Sentiment: Strong Buy

  • Reply to

    FDA discussions will include . . .

    by rehdvm2004 Apr 9, 2014 12:24 PM
    checksurshorts checksurshorts Apr 10, 2014 11:12 PM Flag

    We pulled off 25% cure rate among the "incurable" -- the worst of the worst -- who were not responding to treatment with the big 3 (yes, they were on it during the trial).

    So what is the cure rate for NTM patients (new ones) that receive the big 3?

    And what will the cure rate be for NTM patients receiving Arikace that are treatment naïve (never been treated before)?

    Sentiment: Strong Buy

  • Reply to

    Partners pursuing INSM?

    by mike75x5 Apr 9, 2014 8:59 AM
    checksurshorts checksurshorts Apr 9, 2014 3:55 PM Flag

    Jad- I don't know who the blank you think you are, but you're not supposed to attempt to engage in an intelligent, thought-provoking discussion...this is the Insmed YMB!!!

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 9, 2014 11:36 AM Flag

    I know this set Rehdvm off, but this patient will get what he or she wants according to WL. This will make enrollment go faster and it will be interesting to see the results in treatment naïve patients.

    Sentiment: Strong Buy

  • Reply to

    Negative at last (since it was removed)

    by checksurshorts Apr 5, 2014 12:01 PM
    checksurshorts checksurshorts Apr 9, 2014 11:31 AM Flag

    This is what WL was talking about....a patient in placebo arm reaching culture conversion once receiving drug in 2nd half of trial.

    Sentiment: Strong Buy

  • checksurshorts checksurshorts Apr 7, 2014 6:50 PM Flag

    I'm sure Rehdvm will give us an unbiased account of his 'attendance.'

    Sentiment: Strong Buy

  • checksurshorts checksurshorts Apr 7, 2014 6:40 PM Flag

    Thanks:

    Needham & Company to Host 13th Annual Healthcare Conference, April 8 and 9, 2014

    High-Impact Forum for Biotechnology, Specialty Pharma, Medical Technology and Diagnostics Sectors

    Needham & Company, LLC (Needham & Company) will host its 13th Annual Healthcare Conference at the Westin New York Grand Central Hotel on April 8 and 9, 2014. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies and institutional investors.

    This high-impact forum for institutional investors and venture capital firms will feature updates from senior management of approximately 115 public and private companies in the Biotechnology, Specialty Pharmaceutical, Medical Technology and Diagnostics sectors. The conference format features presentations as well as one-on-one meetings.

    The conference is open to clients of Needham & Company by invitation only. For more information, please call (212) 371-8300

    Sentiment: Strong Buy

  • Reply to

    Compliance with NTM "standard of care"

    by checksurshorts Apr 7, 2014 2:15 PM
    checksurshorts checksurshorts Apr 7, 2014 2:48 PM Flag

    Clone wars here today...talk about deception!

    Sentiment: Strong Buy

  • Arikace (I prefer this spelling) vs. Tobi for CF resulted in "non-inferiority" but context was required. The CC provided that context and we learned that compliance with Tobi (taking both doses daily) is pretty low so the results were not necessarily real-world.

    Could it be that (due to side effects, etc.) that compliance on the big 3 is pretty low as well and that forced compliance during the trial was the reason for the primary endpoint not being met?

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 7, 2014 12:12 PM Flag

    within [an] seemingly extremely complex math formula

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 7, 2014 12:09 PM Flag

    Zake -- I have always felt that he was here to deceive. Terry can post 2+2=5 and most are easily able to see through the deception. But when a scientific "expert" takes that same math problem/bogus answer and encapsulates it within and seemingly extremely complex math formula, many will not even attempt to think it through. Just my opinion. Perhaps he is just a "nutty professor"????

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 7, 2014 11:10 AM Flag

    This is the quote that set him off:

    "I like to forward an email or contact Insmed, the drug company that has developed the drug Arikace. Do you guys know about the Arikace trial? So far I have heard from two patients who claim that they are doing better and are not experiencing any toxicity. However these pple are also taking the big 3 as well - to which they had not responded in the past 2-3 years. In order to be eligible for the Arikace trial, you should continue taking the big 3 even though you have not responded to them which I think does not make sense! And a few days ago I spoke with one of the participating hospitals that is running the Arikace trial and told her about all those pple who cannot take the big 3 or have become immune to them. She told me that they have also been asking Insmed if they could try to test the Arikace alone for those pple who are not on the drug. So they are aware of it. I would like to urge and beg all those people who are not taking the big 3 to contact Insmed and pressure them to open up another trial just to test the drug on them alone without the other antibiotics. I want to have as many pple as possible to contact that company or write letters to them to make the request. I think if lots of us make that request, then they might accept to test the Arikace alone. I think it's worth a try

    Can we all please take action and not just stay impassive and wait for the drug companies to take years and years to finally develop something for us? We don't have much time."

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 6, 2014 12:54 PM Flag

    From the study:

    Key Inclusion Criteria:

    4.Receiving ATS/IDSA guidelines-based treatment regimen defined as: adherent to a multi-drug regimen for at least 6 months prior to screening with persistently positive mycobacterial cultures.

    Key Exclusion Criteria:

    9.Any change in chronic NTM multi-drug regimen within 28 days prior to Study Day 1.

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 6, 2014 12:31 PM Flag

    "WL will quote Dr. Olivier, not the garbage cited above. The only adjuncts that can still be used are 3% saline, Pulmozyme to digest white blood cell "glup", bronchiole dilators and non-antibiotic adjuncts.

    Besides the patient may have gotten placebo in which case the mucous is just thinner"

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 6, 2014 12:29 PM Flag

    "The concept of using "the big three" concurrently would totally confuse what antibiotic effect was attained with Arikace"

    Sentiment: Strong Buy

  • Reply to

    Rehdvm

    by checksurshorts Apr 6, 2014 12:12 PM
    checksurshorts checksurshorts Apr 6, 2014 12:14 PM Flag

    The post is still there from 5/31/13 but I am not able to quote or reply.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Apr 6, 2014 12:12 PM Flag

    Rehdvm2004 scoffed at the idea that NTM trial patients had to be on the big three treatment but Yahoo wont let me post it...pretty funny.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Apr 6, 2014 12:01 PM Flag

    Test.....

INSM
13.41+0.88(+7.02%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.